Precision BioSciences, Inc. (20250127811). MODULATION OF TGF BETA SIGNALING IN GENETICALLY-MODIFIED EUKARYOTIC CELLS
MODULATION OF TGF BETA SIGNALING IN GENETICALLY-MODIFIED EUKARYOTIC CELLS
Organization Name
Inventor(s)
Aaron Martin of Carrboro NC US
MODULATION OF TGF BETA SIGNALING IN GENETICALLY-MODIFIED EUKARYOTIC CELLS
This abstract first appeared for US patent application 20250127811 titled 'MODULATION OF TGF BETA SIGNALING IN GENETICALLY-MODIFIED EUKARYOTIC CELLS
Original Abstract Submitted
the application relates to the field of oncology, cancer immunotherapy, molecular biology and recombinant nucleic acid technology. in particular, the invention relates to genetically-modified eukaryotic cells comprising modulated tgf beta signaling. the application further relates to the use of such genetically-modified eukaryotic cells for treating a disease, including cancer, in a subject.